Over the past decade, BCS has seen an 850% increase1 in the number of claims exceeding $3 million, driven by gene therapies, specialty drug spend, and rising high-cost claimants across rare disease, neonatal, oncology, and complex cardiac care. These multi-million dollar treatments are now common across the industry, and contributing to rising loss ratios and a hardening of the stop loss market. While these conditions have been prevalent throughout the past 18 – 24 months, they will likely continue into the 1/1/2027 sales cycle. The market continues to face downstream pressures including:
- Renewal volatility and increased laser activity
- Tighter underwriting and higher attachment points
- Carrier disruption and reduced market options
- Employer anxiety about long-term plan sustainability
For brokers and consultants advising self-funded employers, placing stop loss coverage at renewal is no longer enough. Employer clients expect strategic guidance on managing and mitigating large claim exposure throughout the plan year. Catastrophic, high-cost claims need to be treated as a systemic risk management challenge, not a transactional insurance placement.
A multi-pronged solution to a complex problem
As with most complex risk problems, no single product closes the gap. Today’s catastrophic claims environment required a coordinated framework that combines financial protection, clinical intervention, and forward planning for emerging treatment categories. The four pillars below define what that framework looks like in practice and where brokers can deliver the most strategic value to self-funded clients.
1. Stop loss anchored in scale and underwriting experience
Stop loss remains foundational for self-funded employers, particularly as claim severity rises. The carriers best positioned to handle today’s risk environment share three traits: decades of underwriting experience in high-severity claims, financial strength ratings that withstand market disruption, and the scale to absorb concentration risk without aggressive lasering.
BCS has served the self-funded market since the 1980s and carries an A (Excellent) rating from A.M. Best. Carrier stability matters most when clients face volatile renewal cycles and shrinking market options. It allows the conversation to shift from carrier churn to long-term risk strategy.
2. Excess reinsurance for high-severity exposure
Excess reinsurance, sometimes called excess of loss, provides additional protection against unpredictable, high-severity claims. While this matters most for health plans and larger employer groups facing concentration risk from high-cost claimants, it is important to note that excess reinsurance can create funding stability and opens options that single-layer stop loss cannot.
3. Dedicated gene therapy risk management
Gene therapies are the fastest-growing category of catastrophic claim exposure, and they do not behave like traditional high-cost claims. The “world’s most expensive drug” title is currently held by Lenmeldy2, a gene therapy priced at $4.25M. Other gene therapies range from $2M to $4M per treatment3.
Coverage triggers, treatment timing, and member eligibility differ dramatically from conventional catastrophic claims. A partner that addresses gene therapy exposure as a distinct risk category, rather than folding it into general stop loss, gives brokers clarity in increasingly complex client discussions.
4. Partnering on cost containment is where brokers create the most client value
Risk transfer alone does not solve the catastrophic claims problem. The differentiating capability is influencing claim outcomes once a high-cost case begins, or even before it materializes.
This means ensuring experienced clinical staff, proactive case analysis, billing audit support, and coordination with patient advocacy organizations. The objective is reducing unnecessary spend while preserving or improving member outcomes, not reducing care. This approach applies to the most complex clinical scenarios, including:
- Rare diseases and complex disorder management
- High-risk maternity and neonatal care
- Cell and gene therapies
- Specialty pharmacy
- Dialysis and oncology
- Trauma, burns, and complex orthopedic cases
- Cardiac events and heart failure
This breadth is why single-product solutions fall short. Brokers need partners equipped for the full range of clinical and financial scenarios their clients will encounter. Recent BCS RiskNavigator cases illustrate the impact:
- A high-risk neonatal case involving a heart transplant generated nearly $1 million in savings through billing audit support after a $5.5 million paid claim
- A hemophilia case originally projected at over $7 million annually produced more than $5 million in savings through treatment coordination with patient advocacy groups, while improving care quality
Outcomes like these reframe the client conversation. Catastrophic claims management is not only about transferring risk. It is about influencing what happens after the claim occurs.
Helping lead the conversation
Catastrophic claims are getting larger, more frequent, and more clinically complex. Brokers who bring strategic framing, not reactive renewal conversations, distinguish themselves in this market.
That framing covers four pillars: financial protection through stop loss, clinical intervention through cost containment, planning for emerging risks like gene therapy, and exploring reinsurance when appropriate.
RiskNavigator is built to support brokers in that role. To discuss how RiskNavigator solutions fit your client book, contact a member of the BCS sales team.
